Evicsgen Establishes Management System Focused on New Drug Development Technology Personnel

DXVX announced on the 11th that it has appointed the new management team of Evixgen, which it recently decided to acquire. Evixgen, in which DXVX decided to acquire approximately 63% of the shares, is a new drug development specialized company with excellent pipelines for ophthalmic diseases such as dry eye syndrome and macular degeneration, as well as atopic dermatitis.

Han Seong-jun, Executive Director of DXVX, has been appointed as the CEO of Evixgen, and the internal directors will also be appointed mainly from new drug development experts. The new management team is scheduled to be finalized after Evixgen’s extraordinary general meeting of shareholders in June next month.

Appointed CEO Han Seong-jun holds a Ph.D. in Biochemistry and Molecular Biology from Paris VI University and was a postdoctoral researcher at the U.S. NIH National Institutes of Health. He is recognized as an expert in infectious disease vaccines and new drug development, having served as the group leader at the Pasteur Institute, which was the first in the world to use the term ‘vaccine.’ He possesses outstanding research capabilities in various new drug developments, including cervical cancer vaccines, hepatitis A vaccines, and peptide formulations, and has previously served as CEO of BHL Bio and Optipharm.

A DXVX official stated, “We will strengthen our new drug development capabilities by composing all of Evixgen’s new management team with Ph.D.-level personnel related to new drug development,” and added, “We plan to further enhance the pipeline value through the successful clinical progress of ophthalmic-related pipelines such as dry eye syndrome and macular degeneration that Evixgen possesses.”

Meanwhile, along with the acquisition of Evixgen, DXVX is actively securing excellent domestic and international talents related to new drug development to accelerate corporate growth and enhance future value, by inviting Dr. Kim Wan-joo, who has led new drug development in Korea, as an advisor, and former Vice President of Korea BMI, Kim Kyung-ho, an expert in clinical trials and regulatory approval, as a technical advisor.

This content was produced with the assistance of AI translation services.